{"success":true,"data":{"pressRelease":{"id":"143045","rtpr_id":"nGNX4YGldZ-20260914","ticker":"VCYT","exchange":"NASDAQ","all_tickers":["VCYT"],"title":"Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform","author":"Globe Newswire","published_at":"2026-09-14T20:05:00.108Z","article_body":"SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc.\n(Nasdaq: VCYT), a leading cancer diagnostics company, today announced its\nacquisition of Convergent Genomics. The acquisition adds Convergent\nGenomics’ UroAmp platform, including its proprietary urinary tumor DNA\n(utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has\nbeen clinically validated in non-muscle invasive bladder cancer (NMIBC),\nincluding therapy-response monitoring and post-treatment surveillance.\n\nIn the U.S., there are approximately 85,000 patients diagnosed with bladder\ncancer annually, including about 65,000 with NMIBC. Of the 750,000 patients\nliving with bladder cancer, approximately 600,000 are living with NMIBC.\n\nNMIBC is generally confined to the bladder and may shed only limited tumor DNA\ninto the bloodstream, which can make blood-based detection challenging. Urine,\nby contrast, comes into direct contact and can provide a highly relevant\nsource of tumor-derived genomic information. UroAmp analyzes this information,\ncreating the potential to help inform treatment decisions and monitor patients\nthroughout their care.\n\n“Bladder cancer care is advancing quickly, yet clinicians and patients still\nface significant uncertainty at critical decision points,” said Marc\nStapley, Veracyte’s chief executive officer. “UroAmp brings a\ndifferentiated urine-based platform that is especially well suited to\nnon-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD\ntests, this acquisition strengthens Veracyte’s ability to deliver\ncomplementary insights from urine, tissue, and blood to help guide care across\nthe bladder cancer continuum.”\n\nUroAmp is supported by a robust and growing body of evidence, including nine\npeer-reviewed publications and more than 40 posters and abstracts.\nVeracyte’s initial test will be intended to help determine whether patients\nwho have completed Bacillus Calmette-Guerin (BCG) induction therapy are likely\nto benefit from maintenance treatment. The company expects to commercialize\nthis test in late 2028, subject to reimbursement timelines. Veracyte also\nplans to expand its use of the UroAmp platform to additional indications,\nincluding intravesical maintenance therapy monitoring and surveillance\nfollowing treatment with curative intent.\n\nIn the RUMBLE study published in The Journal of Urology\n(https://www.globenewswire.com/Tracker?data=R0zTf-5oKTwQliXdCmwhnYDa5_ByQKXb-G0b0lW7xkKbwGzMXYJdmBWoPUY8EQzCnLbyJnxO3exOkKrc-MVGrue532ftE4M4MowYNAZ0GqxGcmh3w3FCItm5poz4TiTu8PaFy3zdvrY0JM5Vj3OgOg==),\na multicenter prospective clinical validation study, patients who were\nclinically negative following induction BCG treatment but tested positive for\nutDNA had a 12-month recurrence-free survival rate of 25%, compared with 91%\namong utDNA-negative patients.(1)\n\n“This acquisition brings together UroAmp’s differentiated platform and\nscientific expertise with Veracyte’s evidence-generation capabilities,\ncommercial infrastructure, and established relationships,” said Brian\nSlingerland, chief executive officer, Convergent Genomics. “We believe this\ncombination can help accelerate the development of new tools that give\nphysicians greater confidence in treatment and monitoring decisions and can\nultimately improve care for people living with bladder cancer.”\n\nThe acquisition includes $150 million in upfront cash consideration and up to\n$30 million in additional cash consideration tied to key milestones related to\nUroAmp reimbursement efforts. Veracyte contemplated the ongoing operating\nexpenses of Convergent in its previously provided 2026 adjusted EBITDA\nguidance and is not updating such guidance at this time.\n\nAbout Convergent Genomics\n\nConvergent Genomics was founded in 2015 by Trevor Levin, PhD, chief scientific\nofficer, and a team of cancer biologists, urologic oncologists, and data\nscientists, in partnership with Oregon Health & Science University (OHSU) and\nIllumina Accelerator. The company has received multiple peer-review grants\nfrom the National Cancer Institute and is engaged in research with over 30\nsites worldwide, including leading academic centers. Convergent Genomics\noperates its clinical laboratory in South San Francisco that is certified by\nthe California Department of Public Health and nationally by CLIA-CMS. For\nmore information visit www.convergentgenomics.com.\n\nAbout Veracyte\n\nVeracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to\ntransform cancer care for patients around the world. The company’s\nmolecular tests assess the unique biology of each patient’s tumor to help\nclinicians answer essential questions about cancer care. Veracyte’s\nDiagnostics Platform\n(https://www.globenewswire.com/Tracker?data=Wd5qkDieU0xsJMtFsRGUkl7ETXxRHvRrwobmEnnhuTM_Lpsj-OrpYbXJfDgskE0NpcCkYslvKWC7vE0nyK-Ez8OZsfQtw7YSoz7y4N53aeg6EH9vyrtsEek5IVOpIJumMKhlezyh69xzCseKYGgt5qxouNcYS8xGiePYhLAxshM=) combines\nbroad genomic and clinical data, advanced bioinformatics and AI, and\na powerful evidence-generation engine to support continued innovation\nand pipeline development\n(https://www.globenewswire.com/Tracker?data=Y1QqcDMvu7E5Iu6HNf1deC1dHxYTfhzyDSre6mEX62CNyPBOKKEIofol4pJgYNECiNGXGFMsg8XmqKfoZV0MGhZabdooQPIpcQE1GAu9fz8O3CxsFkLBLcN-fPzLNtuYIFDuPLqVC8fJ-UTfKkZkLMSUiNH4HNMGs1gK_m1DaeQ=).\nThe company’s portfolio includes the Afirma® Genomic Sequencing\nClassifier test\n(https://www.globenewswire.com/Tracker?data=BIdTOXbwpDz5g04vh-jREpzlJDDsACRJb-wEriAa5udh68E4-PAM-xrA31PJJjq5o0GKTvFqquCbjNyb-AL59o3Nq6iY3qPHaMPkz35_E6InsPlYzFofo0CEhuACgOCMtAILH2JAwEqU4jfHpVqNEGADMtiExJJTrVAEN5-8Et0=), Decipher®\nBladder Genomic Classifier test\n(https://www.globenewswire.com/Tracker?data=NDuOXpy3wiOAo-4oMI6xviAIf4UySObT8ZbKn6FZdGDEa5xptv_W6N7E4PfrmpGdmN0MbW096YllSzu06tKS-TYS78zpMLFEduSv43v6RANms569DX9DmBLM03S72EaJfKW2i6JDGbq5d3n6Jfn4RAbeC70zbOk84A4jJmPEaas=), Decipher®\nProstate Genomic Classifier test\n(https://www.globenewswire.com/Tracker?data=NDuOXpy3wiOAo-4oMI6xvl_lgKoN3zXT2HkzGwu1i6RqcgFAdAn3UR4FYq4fh-n4PFQcOFO9f9JJP0rOr9H-NB40JN8prKBQIMwCACzGFqNjyVZXre_J-Cxs2euuv-LWZiH0rgbDZg43_uwlo9Fx6-4gXtbq-9yoHZbYoOEDYR8=), Prosigna®\nBreast Risk of Recurrence test\n(https://www.globenewswire.com/Tracker?data=W1QkQRgdmAAQTBy1iGImW8Hez5W8qWox-KXVJaC75M-HDAwCZQEuacwb_07mUWRBZm2T0jk9RBlYTPy4ur1TAy3pWxKrXt29-Hjx_LBIcRNgf2zHESu0CdG9fnp1GPGzEJj_Ua5h1ktXmzCKSKXaNw==),\nand the TrueMRD™ Monitoring Test for MIBC\n(https://www.globenewswire.com/Tracker?data=NMv1a4a1gTlmNYXInWGNOid6gAG0m0zueKAvevgTecOiZO_vGJzLnIyVEHD-91SOHtOhvLgtwUmqOzY-qsQAkPAIpCAq6gFbSLJlpsuEv_uGKJc_jUZ8_lMscxMFkXa8KV67_dZ1_Fdtl7043ynOWw==). For\nmore information, visit Veracyte’s website\n(https://www.globenewswire.com/Tracker?data=m2b9cdhsfUcko7YdpgBX4INEoKFzPNByGpJCWe30ulNlPfmfM_k1a6sCGvnFqsbvYtcfhBYDj0GtLhnn42UKEg==) or\nfollow the company on LinkedIn\n(https://www.globenewswire.com/Tracker?data=OHY1_Ok0zayWXKjnR78jHQN3u-RQ4Pmntt53DjOiyWBDxosMNTTeK7CppAsx2EwcRGzkAAcuGOFiJxwCgjcrHEUqiW3L4_NBdpmpR6Qt9LU=) or X\n(Twitter)\n(https://www.globenewswire.com/Tracker?data=ELLMhnlLb9ZDj7AuGcKCb7C1wthwcGGb9UsQEWezYtdaGm6auN0TAeCH9qOwoI-qYVZ473Mtk66q6azqPq84Og==).\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nregarding the anticipated short and long term strategic, clinical, commercial\nand financial benefits of the acquisition; the expected impact of the\nacquisition on Veracyte’s near-term financial outlook; development, launch,\ncommercialization, reimbursement and timing of tests based on the acquired\ntechnology, including UroAmp; the anticipated timing of launch of the first\nproduct; estimated market opportunities; potential commercial synergies;\npotential applications of UroAmp in other urological diseases; and ability to\nachieve anticipated milestones.\n\nForward-looking statements can be identified by words such as\n“anticipate,” “believe,” “expect,” “intend,” “may,”\n“plan,” “potential,” “will,” “could” and similar expressions.\nActual results may differ materially due to risks and uncertainties, including\nVeracyte’s ability to integrate Convergent, retain key employees, achieve\nanticipated benefits of the acquisition, meet development timelines,\ndemonstrate clinical validity and utility of acquired products, obtain\nreimbursement for acquired products and commercialize new tests, including\nUroAmp.\n\nAdditional factors are described under “Risk Factors” in Veracyte’s most\nrecent Annual Report on Form 10-K and subsequent filings with the Securities\nand Exchange Commission. These statements speak only as of the date of this\nrelease, and Veracyte disclaims any obligation to update them except as\nrequired by law.\n\nInvestors:\nKelly Gura\ninvestors@veracyte.com\n\nMedia:\nMolly Cornbleet\nmedia@veracyte.com\n+1 650-351-8780\n\n(1) Bahlburg H, Maas M, Contreras-Sanz A, et al. Urine tumor DNA testing\nidentifies recurrence and monitors therapy response in patients with high-risk\nnon-muscle-invasive bladder cancer receiving intravesical bacillus\nCalmette-Guérin. J Urol. 2026;216(3):388-399.\ndoi:10.1097/JU.0000000000005130.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cd03c874-765a-4f63-85f9-9438bda7775f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4YGldZ-20260914","title":"Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform","author":"Globe Newswire","ticker":"VCYT","created":"2026-09-14T20:05:00.108Z","tickers":["VCYT"],"exchange":"NASDAQ","article_body":"SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc.\n(Nasdaq: VCYT), a leading cancer diagnostics company, today announced its\nacquisition of Convergent Genomics. The acquisition adds Convergent\nGenomics’ UroAmp platform, including its proprietary urinary tumor DNA\n(utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has\nbeen clinically validated in non-muscle invasive bladder cancer (NMIBC),\nincluding therapy-response monitoring and post-treatment surveillance.\n\nIn the U.S., there are approximately 85,000 patients diagnosed with bladder\ncancer annually, including about 65,000 with NMIBC. Of the 750,000 patients\nliving with bladder cancer, approximately 600,000 are living with NMIBC.\n\nNMIBC is generally confined to the bladder and may shed only limited tumor DNA\ninto the bloodstream, which can make blood-based detection challenging. Urine,\nby contrast, comes into direct contact and can provide a highly relevant\nsource of tumor-derived genomic information. UroAmp analyzes this information,\ncreating the potential to help inform treatment decisions and monitor patients\nthroughout their care.\n\n“Bladder cancer care is advancing quickly, yet clinicians and patients still\nface significant uncertainty at critical decision points,” said Marc\nStapley, Veracyte’s chief executive officer. “UroAmp brings a\ndifferentiated urine-based platform that is especially well suited to\nnon-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD\ntests, this acquisition strengthens Veracyte’s ability to deliver\ncomplementary insights from urine, tissue, and blood to help guide care across\nthe bladder cancer continuum.”\n\nUroAmp is supported by a robust and growing body of evidence, including nine\npeer-reviewed publications and more than 40 posters and abstracts.\nVeracyte’s initial test will be intended to help determine whether patients\nwho have completed Bacillus Calmette-Guerin (BCG) induction therapy are likely\nto benefit from maintenance treatment. The company expects to commercialize\nthis test in late 2028, subject to reimbursement timelines. Veracyte also\nplans to expand its use of the UroAmp platform to additional indications,\nincluding intravesical maintenance therapy monitoring and surveillance\nfollowing treatment with curative intent.\n\nIn the RUMBLE study published in The Journal of Urology\n(https://www.globenewswire.com/Tracker?data=R0zTf-5oKTwQliXdCmwhnYDa5_ByQKXb-G0b0lW7xkKbwGzMXYJdmBWoPUY8EQzCnLbyJnxO3exOkKrc-MVGrue532ftE4M4MowYNAZ0GqxGcmh3w3FCItm5poz4TiTu8PaFy3zdvrY0JM5Vj3OgOg==),\na multicenter prospective clinical validation study, patients who were\nclinically negative following induction BCG treatment but tested positive for\nutDNA had a 12-month recurrence-free survival rate of 25%, compared with 91%\namong utDNA-negative patients.(1)\n\n“This acquisition brings together UroAmp’s differentiated platform and\nscientific expertise with Veracyte’s evidence-generation capabilities,\ncommercial infrastructure, and established relationships,” said Brian\nSlingerland, chief executive officer, Convergent Genomics. “We believe this\ncombination can help accelerate the development of new tools that give\nphysicians greater confidence in treatment and monitoring decisions and can\nultimately improve care for people living with bladder cancer.”\n\nThe acquisition includes $150 million in upfront cash consideration and up to\n$30 million in additional cash consideration tied to key milestones related to\nUroAmp reimbursement efforts. Veracyte contemplated the ongoing operating\nexpenses of Convergent in its previously provided 2026 adjusted EBITDA\nguidance and is not updating such guidance at this time.\n\nAbout Convergent Genomics\n\nConvergent Genomics was founded in 2015 by Trevor Levin, PhD, chief scientific\nofficer, and a team of cancer biologists, urologic oncologists, and data\nscientists, in partnership with Oregon Health & Science University (OHSU) and\nIllumina Accelerator. The company has received multiple peer-review grants\nfrom the National Cancer Institute and is engaged in research with over 30\nsites worldwide, including leading academic centers. Convergent Genomics\noperates its clinical laboratory in South San Francisco that is certified by\nthe California Department of Public Health and nationally by CLIA-CMS. For\nmore information visit www.convergentgenomics.com.\n\nAbout Veracyte\n\nVeracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to\ntransform cancer care for patients around the world. The company’s\nmolecular tests assess the unique biology of each patient’s tumor to help\nclinicians answer essential questions about cancer care. Veracyte’s\nDiagnostics Platform\n(https://www.globenewswire.com/Tracker?data=Wd5qkDieU0xsJMtFsRGUkl7ETXxRHvRrwobmEnnhuTM_Lpsj-OrpYbXJfDgskE0NpcCkYslvKWC7vE0nyK-Ez8OZsfQtw7YSoz7y4N53aeg6EH9vyrtsEek5IVOpIJumMKhlezyh69xzCseKYGgt5qxouNcYS8xGiePYhLAxshM=) combines\nbroad genomic and clinical data, advanced bioinformatics and AI, and\na powerful evidence-generation engine to support continued innovation\nand pipeline development\n(https://www.globenewswire.com/Tracker?data=Y1QqcDMvu7E5Iu6HNf1deC1dHxYTfhzyDSre6mEX62CNyPBOKKEIofol4pJgYNECiNGXGFMsg8XmqKfoZV0MGhZabdooQPIpcQE1GAu9fz8O3CxsFkLBLcN-fPzLNtuYIFDuPLqVC8fJ-UTfKkZkLMSUiNH4HNMGs1gK_m1DaeQ=).\nThe company’s portfolio includes the Afirma® Genomic Sequencing\nClassifier test\n(https://www.globenewswire.com/Tracker?data=BIdTOXbwpDz5g04vh-jREpzlJDDsACRJb-wEriAa5udh68E4-PAM-xrA31PJJjq5o0GKTvFqquCbjNyb-AL59o3Nq6iY3qPHaMPkz35_E6InsPlYzFofo0CEhuACgOCMtAILH2JAwEqU4jfHpVqNEGADMtiExJJTrVAEN5-8Et0=), Decipher®\nBladder Genomic Classifier test\n(https://www.globenewswire.com/Tracker?data=NDuOXpy3wiOAo-4oMI6xviAIf4UySObT8ZbKn6FZdGDEa5xptv_W6N7E4PfrmpGdmN0MbW096YllSzu06tKS-TYS78zpMLFEduSv43v6RANms569DX9DmBLM03S72EaJfKW2i6JDGbq5d3n6Jfn4RAbeC70zbOk84A4jJmPEaas=), Decipher®\nProstate Genomic Classifier test\n(https://www.globenewswire.com/Tracker?data=NDuOXpy3wiOAo-4oMI6xvl_lgKoN3zXT2HkzGwu1i6RqcgFAdAn3UR4FYq4fh-n4PFQcOFO9f9JJP0rOr9H-NB40JN8prKBQIMwCACzGFqNjyVZXre_J-Cxs2euuv-LWZiH0rgbDZg43_uwlo9Fx6-4gXtbq-9yoHZbYoOEDYR8=), Prosigna®\nBreast Risk of Recurrence test\n(https://www.globenewswire.com/Tracker?data=W1QkQRgdmAAQTBy1iGImW8Hez5W8qWox-KXVJaC75M-HDAwCZQEuacwb_07mUWRBZm2T0jk9RBlYTPy4ur1TAy3pWxKrXt29-Hjx_LBIcRNgf2zHESu0CdG9fnp1GPGzEJj_Ua5h1ktXmzCKSKXaNw==),\nand the TrueMRD™ Monitoring Test for MIBC\n(https://www.globenewswire.com/Tracker?data=NMv1a4a1gTlmNYXInWGNOid6gAG0m0zueKAvevgTecOiZO_vGJzLnIyVEHD-91SOHtOhvLgtwUmqOzY-qsQAkPAIpCAq6gFbSLJlpsuEv_uGKJc_jUZ8_lMscxMFkXa8KV67_dZ1_Fdtl7043ynOWw==). For\nmore information, visit Veracyte’s website\n(https://www.globenewswire.com/Tracker?data=m2b9cdhsfUcko7YdpgBX4INEoKFzPNByGpJCWe30ulNlPfmfM_k1a6sCGvnFqsbvYtcfhBYDj0GtLhnn42UKEg==) or\nfollow the company on LinkedIn\n(https://www.globenewswire.com/Tracker?data=OHY1_Ok0zayWXKjnR78jHQN3u-RQ4Pmntt53DjOiyWBDxosMNTTeK7CppAsx2EwcRGzkAAcuGOFiJxwCgjcrHEUqiW3L4_NBdpmpR6Qt9LU=) or X\n(Twitter)\n(https://www.globenewswire.com/Tracker?data=ELLMhnlLb9ZDj7AuGcKCb7C1wthwcGGb9UsQEWezYtdaGm6auN0TAeCH9qOwoI-qYVZ473Mtk66q6azqPq84Og==).\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nregarding the anticipated short and long term strategic, clinical, commercial\nand financial benefits of the acquisition; the expected impact of the\nacquisition on Veracyte’s near-term financial outlook; development, launch,\ncommercialization, reimbursement and timing of tests based on the acquired\ntechnology, including UroAmp; the anticipated timing of launch of the first\nproduct; estimated market opportunities; potential commercial synergies;\npotential applications of UroAmp in other urological diseases; and ability to\nachieve anticipated milestones.\n\nForward-looking statements can be identified by words such as\n“anticipate,” “believe,” “expect,” “intend,” “may,”\n“plan,” “potential,” “will,” “could” and similar expressions.\nActual results may differ materially due to risks and uncertainties, including\nVeracyte’s ability to integrate Convergent, retain key employees, achieve\nanticipated benefits of the acquisition, meet development timelines,\ndemonstrate clinical validity and utility of acquired products, obtain\nreimbursement for acquired products and commercialize new tests, including\nUroAmp.\n\nAdditional factors are described under “Risk Factors” in Veracyte’s most\nrecent Annual Report on Form 10-K and subsequent filings with the Securities\nand Exchange Commission. These statements speak only as of the date of this\nrelease, and Veracyte disclaims any obligation to update them except as\nrequired by law.\n\nInvestors:\nKelly Gura\ninvestors@veracyte.com\n\nMedia:\nMolly Cornbleet\nmedia@veracyte.com\n+1 650-351-8780\n\n(1) Bahlburg H, Maas M, Contreras-Sanz A, et al. Urine tumor DNA testing\nidentifies recurrence and monitors therapy response in patients with high-risk\nnon-muscle-invasive bladder cancer receiving intravesical bacillus\nCalmette-Guérin. J Urol. 2026;216(3):388-399.\ndoi:10.1097/JU.0000000000005130.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cd03c874-765a-4f63-85f9-9438bda7775f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-14T20:05:00.157657726Z","server_sent_at_ms":1789416300157},"received_at":"2026-09-14T20:05:00.297Z","source_url":null},"analysis":{"id":"131889","press_release_id":"143045","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["first UroAmp-derived test not expected to commercialize until late 2028 and is dependent on reimbursement timelines","no near-term financial contribution — 2026 adjusted EBITDA guidance unchanged","$30 million of the consideration is contingent on reimbursement milestones","integration and reimbursement risks explicitly cited in forward-looking statements"],"eventType":"m_and_a","narrative":"Veracyte has acquired Convergent Genomics, adding the UroAmp platform and its proprietary urinary tumor DNA (utDNA) technology to Veracyte's urology diagnostics portfolio alongside its Decipher Bladder and TrueMRD tests.\n\nDeal terms comprise $150 million in upfront cash plus up to $30 million in milestone payments tied to UroAmp reimbursement efforts; Veracyte's 2026 adjusted EBITDA guidance already contemplated Convergent's operating expenses and is unchanged.\n\nThe first planned test would identify non-muscle invasive bladder cancer patients likely to benefit from BCG maintenance therapy, with commercialization targeted for late 2028 subject to reimbursement timelines.\n\nIn the RUMBLE prospective validation study, utDNA-positive patients after induction BCG had a 25% 12-month recurrence-free survival rate versus 91% for utDNA-negative patients, in a U.S. market of roughly 85,000 annual bladder cancer diagnoses.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Veracyte deepens its urology franchise with a $150M upfront bolt-on for urinary tumor DNA testing — a strategic fit today, but a 2028 revenue story."},"keyFigures":{"guidance":"2026 adjusted EBITDA guidance unchanged; Convergent Genomics operating expenses already contemplated in prior guidance","dealValueUsd":150000000,"customDimensions":{"first_test_launch":"late 2028, subject to reimbursement timelines","milestone_consideration":"up to $30 million tied to UroAmp reimbursement milestones","peer_reviewed_publications":9,"upfront_cash_consideration":"$150 million","us_nmibc_diagnoses_annually":65000,"rumble_12mo_rfs_utdna_negative":"91%","rumble_12mo_rfs_utdna_positive":"25%","us_bladder_cancer_diagnoses_annually":85000}},"quotedText":"Bladder cancer care is advancing quickly, yet clinicians and patients still\nface significant uncertainty at critical decision points","namedEntities":{"people":[{"name":"Marc Stapley","role":"CEO, Veracyte"},{"name":"Brian Slingerland","role":"CEO, Convergent Genomics"},{"name":"Trevor Levin, PhD","role":"Founder and Chief Scientific Officer, Convergent Genomics"}],"products":["UroAmp","Decipher Bladder Genomic Classifier","TrueMRD Monitoring Test for MIBC","Afirma Genomic Sequencing Classifier","Decipher Prostate Genomic Classifier","Prosigna Breast Risk of Recurrence"],"companies":[{"name":"Veracyte, Inc.","ticker":"VCYT","relationship":"acquirer / filer"},{"name":"Convergent Genomics","relationship":"target"},{"name":"Oregon Health & Science University (OHSU)","relationship":"research partner of target"},{"name":"Illumina Accelerator","relationship":"incubator partner of target"},{"name":"National Cancer Institute","relationship":"grant funder of target"}],"dollarAmounts":[{"amount":"$150 million","context":"upfront cash consideration for the Convergent Genomics acquisition"},{"amount":"$30 million","context":"additional cash consideration tied to UroAmp reimbursement milestones"}]},"materialImpact":{"score":4,"reasoning":"Definitive acquisition with $150 million upfront cash plus up to $30 million in milestone consideration — a strategically significant bolt-on that deepens Veracyte's urology franchise. Financial impact is deferred (first test launches late 2028, guidance unchanged), so not a 5."},"tickerRelevance":{"others":[],"primary":"VCYT"},"globalImportance":38,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"bolt-on M&A, $150M upfront / up to $180M total potential","strategicFit":"strong — expands urology diagnostics continuum (urine, tissue, blood)","nearTermFinancialImpact":"none — guidance unchanged, launch in late 2028","reimbursementDependency":true}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Veracyte has acquired Convergent Genomics, adding the UroAmp platform and its proprietary urinary tumor DNA (utDNA) technology to Veracyte's urology diagnostics portfolio alongside its Decipher Bladder and TrueMRD tests.\n\nDeal terms comprise $150 million in upfront cash plus up to $30 million in milestone payments tied to UroAmp reimbursement efforts; Veracyte's 2026 adjusted EBITDA guidance already contemplated Convergent's operating expenses and is unchanged.\n\nThe first planned test would identify non-muscle invasive bladder cancer patients likely to benefit from BCG maintenance therapy, with commercialization targeted for late 2028 subject to reimbursement timelines.\n\nIn the RUMBLE prospective validation study, utDNA-positive patients after induction BCG had a 25% 12-month recurrence-free survival rate versus 91% for utDNA-negative patients, in a U.S. market of roughly 85,000 annual bladder cancer diagnoses.","key_figures":{"guidance":"2026 adjusted EBITDA guidance unchanged; Convergent Genomics operating expenses already contemplated in prior guidance","dealValueUsd":150000000,"customDimensions":{"first_test_launch":"late 2028, subject to reimbursement timelines","milestone_consideration":"up to $30 million tied to UroAmp reimbursement milestones","peer_reviewed_publications":9,"upfront_cash_consideration":"$150 million","us_nmibc_diagnoses_annually":65000,"rumble_12mo_rfs_utdna_negative":"91%","rumble_12mo_rfs_utdna_positive":"25%","us_bladder_cancer_diagnoses_annually":85000}},"named_entities":{"people":[{"name":"Marc Stapley","role":"CEO, Veracyte"},{"name":"Brian Slingerland","role":"CEO, Convergent Genomics"},{"name":"Trevor Levin, PhD","role":"Founder and Chief Scientific Officer, Convergent Genomics"}],"products":["UroAmp","Decipher Bladder Genomic Classifier","TrueMRD Monitoring Test for MIBC","Afirma Genomic Sequencing Classifier","Decipher Prostate Genomic Classifier","Prosigna Breast Risk of Recurrence"],"companies":[{"name":"Veracyte, Inc.","ticker":"VCYT","relationship":"acquirer / filer"},{"name":"Convergent Genomics","relationship":"target"},{"name":"Oregon Health & Science University (OHSU)","relationship":"research partner of target"},{"name":"Illumina Accelerator","relationship":"incubator partner of target"},{"name":"National Cancer Institute","relationship":"grant funder of target"}],"dollarAmounts":[{"amount":"$150 million","context":"upfront cash consideration for the Convergent Genomics acquisition"},{"amount":"$30 million","context":"additional cash consideration tied to UroAmp reimbursement milestones"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-14T20:05:53.704Z","global_importance":38,"audience_relevance":30,"importance_components":{"tickerTier":"mid-cap","eventGravity":"bolt-on M&A, $150M upfront / up to $180M total potential","strategicFit":"strong — expands urology diagnostics continuum (urine, tissue, blood)","nearTermFinancialImpact":"none — guidance unchanged, launch in late 2028","reimbursementDependency":true}},"durationMs":53396,"modelName":"glm-5.3-flash"}}